What Innovation Zed does

Innovation Zed is an Ireland-based medical device company founded in 2009 that designs, researches, and develops smart connected solutions for drug delivery devices, with a primary focus on the metabolic health market and Multiple Daily Injection (MDI) diabetes therapy. Its core technology combines a third-generation hardware add-on device (InsulCheck DOSE) that automatically captures dose value, injection event timestamps, pen temperature, and mounting/unmounting data from both reusable and disposable insulin pens, with a companion mobile app (InsulCheck SAOR) available on iOS and Android that enables real-time CGM data integration and automated insulin logging. The two components together form the SAOR system, which provides 24/7 monitoring across insulin injection and CGM data for a 7+ day battery life, replacing manual dose diaries with continuous, automated therapy records.

The platform architecture is deliberately pen-agnostic — it transforms any standard insulin pen into a connected smart pen without requiring patients to switch their existing medication — and is configurable across multiple therapy areas including Diabetes, Obesity, Growth Hormone, Fertility, Migraines, and Arthritis. Manufacturing is executed through a long-standing OEM partnership with SHL Medical established in 2016, a leading autoinjector manufacturer with 30+ years of experience serving global pharmaceutical companies; SHL leadership also sits on the Innovation Zed board, including the Chairman role.

The company operates a product-led growth model with direct-to-consumer distribution through the iOS App Store and Google Play Store, currently running a SAOR BETA Launch enrollment program. The commercial model combines hardware device sales (InsulCheck DOSE) with a subscription-style companion app (InsulCheck SAOR), targeting MDI diabetes patients who need automated injection tracking and correlation with glucose data. The company is small (1-10 employees), privately held, headquartered in Dublin, and is not currently disclosing revenue, funding, or enterprise customer logos.

Name

Innovation Zed

Legal name

Innovation Zed

Website

https://innovationzed.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

Innovation Zed designs smart connected solutions for insulin injection pens, combining the InsulCheck DOSE hardware add-on with the InsulCheck SAOR mobile app to automate dose logging and CGM integration for MDI diabetes patients and adjacent therapy areas.

Ownership category

akta.pro rank

Product category

Connected Diabetes Management Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Smart Insulin Pens & Connected Pen Caps (HLAHAHAD)

akta.pro secondary industries

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC)

Keywords

• Connected injection pens
• Diabetes management system
• Insulin pen monitoring
• Smart drug delivery
• MDI therapy tracking

Headquarters

HQ city

Dublin

HQ country

Ireland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Hardware Device Sales (InsulCheck DOSE): Sale of the InsulCheck DOSE add-on device that attaches to insulin pens to capture injection data. The device is sold as a physical product that enables the smart pen functionality.
2. Software Subscription (InsulCheck SAOR App): Companion mobile app providing real-time data logging, CGM integration, and diabetes management features. Available on iOS and Android platforms.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Innovation Zed designs, develops, and sells the SAOR diabetes management system for people on multiple daily injection (MDI) insulin therapy. The system combines the InsulCheck DOSE add-on hardware device, which attaches to standard reusable or disposable insulin pens to automatically capture dose value, injection timestamp, temperature, and mounting data, with the InsulCheck SAOR companion mobile app (iOS and Android) that logs injection events in real time and integrates continuous glucose monitor (CGM) data. Together the products transform any existing insulin pen into a connected smart pen with 24/7 monitoring.

Product overview

Innovation Zed offers a unified diabetes management platform consisting of two integrated products: InsulCheck DOSE (a hardware add-on device for insulin pens) and InsulCheck SAOR (a companion mobile app). Together, these products form the SAOR system, which transforms any standard insulin pen into a connected smart pen that automatically captures injection data including dose value, timestamps, and temperature. The platform supports both bolus and basal insulin pens and can integrate real-time CGM data.

Differentiator

Problem solved

Functional benefit

Brands

• InsulCheck DOSE: Third-generation platform technology - a single component add-on device for injection pens that automatically captures dose value dialed, injection event timestamp, temperature and mounting/unmounting data.
• InsulCheck SAOR
• SAOR

Products and services

• SAOR

Quantifiable outcome

• 7+ day battery life

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• SHL MedicalcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2016Innovation Zed established a partnership with SHL Medical in 2016. SHL Medical specializes in the design and manufacturing of medical devices with over 30 years of experience producing easy-to-use self-injection devices for global pharmaceutical companies. The partnership ensures products are produced to the highest quality standards.

Scale indicators2 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Novo Nordisk (NovoPen 6 / NovoPen Echo Plus): Novo Nordisk's NovoPen 6 and Echo Plus are durable connected insulin pens that capture dosing data and pair with apps; as a pharma-incumbent smart pen, they compete for the same patient workflows that SAOR targets.
• Eli Lilly (Tempo Smart Button / Tempo Pen): Lilly's Tempo Smart Button and Tempo Pen attach to its prefilled insulin pens to transmit dose data via Bluetooth — a directly competing connected-pen approach from a major insulin manufacturer with deep channel control.
• Sanofi (Insulin Pen Digital Ecosystem): Sanofi has been pairing its connected insulin pens with diabetes management software partners (e.g., Insulia, mySugr integrations) — a competitor ecosystem for connected MDI therapy data capture.
• Abbott (FreeStyle Libre / Bigfoot acquisition): Abbott's FreeStyle Libre CGM is a primary integration target for MDI smart-pen systems and the company acquired Bigfoot Unity assets — positioning Abbott as both a potential partner and platform competitor to SAOR.

Others

• Dexcom: Dexcom is the leading CGM manufacturer and a natural ecosystem partner for SAOR's CGM-injection integration feature; it also offers its own diabetes management companion apps that compete for the same patient workflow.

Emerging players

• Common Sensing: Cambridge-based Common Sensing built Gocap, a connected cap for injectable medications that captures dose and timing data — a closely related connected-injection-device concept targeting the same use case as SAOR.

Direct peers

• Bigfoot Biomedical: Bigfoot built the Bigfoot Unity smart insulin pen cap system that automatically captures dose data from disposable insulin pens for MDI users — the closest direct analogue to Innovation Zed's InsulCheck DOSE add-on device concept.
• Emperra GmbH (Easypod / Esysta): Emperra has developed Esysta, a connected insulin pen system that captures dose, time and type of insulin and transmits to a diabetes management platform — directly competing in the automated injection-tracking category.
• Biocorp (NovaPen / Mallya): French medtech Biocorp develops Mallya, a Bluetooth smart cap/add-on for insulin pens that automatically captures injection data and pairs with apps — a direct functional competitor to InsulCheck DOSE.
• Medtronic (InPen): Medtronic's InPen is a Bluetooth-connected reusable insulin pen with companion app that captures dose data and integrates CGM for MDI users, competing head-to-head with SAOR in the connected MDI therapy category.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/InnovationZed
• YouTubeyoutube.com/@innovationzed523
• Facebookfacebook.com/InnovationZed
• LinkedInlinkedin.com/company/innovationzed

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innovation Zed